Sandbox Reserved 1652: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 83: | Line 83: | ||
This receptor exists under 3 different forms and ethanol is able to activate this receptor. | This receptor exists under 3 different forms and ethanol is able to activate this receptor. | ||
In 2011 Qutenza (NeurogesX) patch containing 8% of capsaicin has been marketed in France and indicated in the [https://en.wikipedia.org/wiki/Neuropathic_pain neuropathic pain]. | In 2011 Qutenza (NeurogesX) patch containing 8% of capsaicin has been marketed in France and indicated in the [https://en.wikipedia.org/wiki/Neuropathic_pain neuropathic pain]. | ||
The absorption through the skin of these creams generated partial desensitization of the nerve endings. This is the cause of a decrease in painful sensations.<ref name="TRPV1 dans les neuropathies douloureuses - Des modèles animaux aux perspectives thérapeutiques" | The absorption through the skin of these creams generated partial desensitization of the nerve endings. This is the cause of a decrease in painful sensations.<ref name="TRPV1 dans les neuropathies douloureuses - Des modèles animaux aux perspectives thérapeutiques"> A. Danigo, L. Magy, et C. Demiot, « TRPV1 dans les neuropathies douloureuses - Des modèles animaux aux perspectives thérapeutiques », médecine/sciences, vol. 29, no 6‑7, Art. no 6‑7, juin 2013, doi: 10.1051/medsci/2013296012.</ref> | ||
[https://en.wikipedia.org/wiki/Capsazepine Capsazepine] is a synthetic competitive antagonist of this receptor which is currently used to study TRPV1 function. | [https://en.wikipedia.org/wiki/Capsazepine Capsazepine] is a synthetic competitive antagonist of this receptor which is currently used to study TRPV1 function. | ||
Many laboratories are conducting clinical studies on oral TRPV1 antagonists: [https://fr.wikipedia.org/wiki/GlaxoSmithKline GlaxoSmithKline ], [https://en.wikipedia.org/wiki/Amgen Amgen], [https://en.wikipedia.org/wiki/Merck_%26_Co. Merck]-Neurogen, [https://en.wikipedia.org/wiki/Abbott_Laboratories Abbott], [https://en.wikipedia.org/wiki/Eli_Lilly_and_Company Eli Lilly], [https://en.wikipedia.org/wiki/AstraZeneca AstraZeneca] and [https://en.wikipedia.org/wiki/Japan_Tobacco Japan Tobacco]. Nowadays at least seven orally active TRPV1 antagonist substances successfully went for clinical development and the laboratories cited before all completed phase I trials . However some of them have stopped their researches at phase II trials by unknown reason as GlaxoSmithKline | Many laboratories are conducting clinical studies on oral TRPV1 antagonists: [https://fr.wikipedia.org/wiki/GlaxoSmithKline GlaxoSmithKline ], [https://en.wikipedia.org/wiki/Amgen Amgen], [https://en.wikipedia.org/wiki/Merck_%26_Co. Merck]-Neurogen, [https://en.wikipedia.org/wiki/Abbott_Laboratories Abbott], [https://en.wikipedia.org/wiki/Eli_Lilly_and_Company Eli Lilly], [https://en.wikipedia.org/wiki/AstraZeneca AstraZeneca] and [https://en.wikipedia.org/wiki/Japan_Tobacco Japan Tobacco]. Nowadays at least seven orally active TRPV1 antagonist substances successfully went for clinical development and the laboratories cited before all completed phase I trials . However some of them have stopped their researches at phase II trials by unknown reason as GlaxoSmithKline | ||
